Aarkstore - Wounds - Pipeline Review, H2 2014

1
Wounds - Pipeline Review, H2 2014
Category Pharmaceuticals Healthcare 

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/63080/wounds-pipeline-review

2
Wounds - Pipeline Review, H2 2014
3
Summary

• Global Markets Directs, Wounds - Pipeline
  Review, H2 2014, provides an overview of the
  Woundss therapeutic pipeline.This report
  provides comprehensive information on the
  therapeutic development for Wounds, complete with
  comparative analysis at various stages,
  therapeutics assessment by drug target, mechanism
  of action (MoA), route of administration (RoA)
  and molecule type, along with latest updates, and
  featured news and press releases. It also reviews
  key players involved in the therapeutic
  development for Wounds and special features on
  late-stage and discontinued projects.
• Global Markets Directs report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, Company/University
  websites, SEC filings, investor presentations and
  featured press releases from company/university
  sites and industry-specific third party sources,
  put together by Global Markets Directs team.

4
Summary

• Drug profiles/records featured in the report
  undergoes periodic updation following a stringent
  set of processes that ensures that all the
  profiles are updated with the latest set of
  information. Additionally, processes including
  live news deals tracking, browser based
  alert-box and clinical trials registries tracking
  ensure that the most recent developments are
  captured on a real time basis.
• The report enhances decision making capabilities
  and help to create effective counter strategies
  to gain competitive advantage. It strengthens RD
  pipelines by identifying new targets and MOAs to
  produce first-in-class and best-in-class
  products.Note Certain sections in the report
  may be removed or altered based on the
  availability and relevance of data for the
  indicated disease.

5
Scope

• - The report provides a snapshot of the global
  therapeutic landscape of Wounds- The report
  reviews key pipeline products under drug profile
  section which includes, product description, MoA
  and RD brief, licensing and collaboration
  details other developmental activities - The
  report reviews key players involved in the
  therapeutics development for Wounds and enlists
  all their major and minor projects- The report
  summarizes all the dormant and discontinued
  pipeline projects - A review of the Wounds
  products under development by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources- Pipeline products
  coverage based on various stages of development
  ranging from pre-registration till discovery and
  undisclosed stages- A detailed assessment of
  monotherapy and combination therapy pipeline
  projects- Coverage of the Wounds pipeline on the
  basis of target, MoA, route of administration and
  molecule type- Latest news and deals relating
  related to pipeline products

6
Reasons to buy

• - Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies- Identify
  emerging players with potentially strong product
  portfolio and create effective counter-strategies
  to gain competitive advantage- Develop strategic
  initiatives by understanding the focus areas of
  leading companies- Identify and understand
  important and diverse types of therapeutics under
  development for Wounds- Plan mergers and
  acquisitions effectively by identifying key
  players of the most promising pipeline- Devise
  corrective measures for pipeline projects by
  understanding Wounds pipeline depth and focus of
  Indication therapeutics- Develop and design
  in-licensing and out-licensing strategies by
  identifying prospective partners with the most
  attractive projects to enhance and expand
  business potential and scope- Modify the
  therapeutic portfolio by identifying discontinued
  projects and understanding the factors that drove
  them from pipeline

7
Table of Content
List of Tables 7List of Figures 9Introduction
10Global Markets Direct Report Coverage
10Wounds Overview 11Therapeutics Development
12Pipeline Products for Wounds - Overview
12Pipeline Products for Wounds - Comparative
Analysis 13Wounds - Therapeutics under
Development by Companies 14Wounds - Therapeutics
under Investigation by Universities/Institutes
20Wounds - Pipeline Products Glance 22Late
Stage Products 22Clinical Stage Products
23Early Stage Products 24Unknown Stage Products
25Wounds - Products under Development by
Companies 26
8
Table of Content
Wounds - Products under Investigation by
Universities/Institutes 31Wounds - Companies
Involved in Therapeutics Development 33Advancell
33Aerpio Therapeutics, Inc. 34AlgiPharma AS
35AndroScience Corporation 36AnGes MG, Inc.
37APEIRON Biologics AG 38Apricus Biosciences,
Inc. 39Aridis Pharmaceuticals LLC 40Beech Tree
Labs, Inc. 41Bio3 Research S.r.l 42Biotec
Pharmacon ASA 43Birken AG 44Blueberry
Therapeutics Ltd 45
9
List Of Tables

• Number of Products under Development for Wounds,
  H2 2014 18Number of Products under Development
  for Wounds - Comparative Analysis, H2 2014
  19Number of Products under Development by
  Companies, H2 2014 21Number of Products under
  Development by Companies, H2 2014 (Contd..1)
  22Number of Products under Development by
  Companies, H2 2014 (Contd..2) 23Number of
  Products under Development by Companies, H2 2014
  (Contd..3) 24Number of Products under
  Development by Companies, H2 2014 (Contd..4)
  25Number of Products under Investigation by
  Universities/Institutes, H2 2014 27Comparative
  Analysis by Late Stage Development, H2 2014
  28Comparative Analysis by Clinical Stage
  Development, H2 2014 29Comparative Analysis by
  Early Stage Development, H2 2014 30Comparative
  Analysis by Unknown Stage Development, H2 2014
  31

10
List Of Tables

• Products under Development by Companies, H2 2014
  32Products under Development by Companies, H2
  2014 (Contd..1) 33Products under Development by
  Companies, H2 2014 (Contd..2) 34Products under
  Development by Companies, H2 2014 (Contd..3)
  35Products under Development by Companies, H2
  2014 (Contd..4) 36Products under Investigation
  by Universities/Institutes, H2 2014 37Products
  under Investigation by Universities/Institutes,
  H2 2014 (Contd..1) 38Wounds - Pipeline by
  Advancell, H2 2014 39Wounds - Pipeline by Aerpio
  Therapeutics, Inc., H2 2014 40Wounds - Pipeline
  by AlgiPharma AS, H2 2014 41Wounds - Pipeline by
  AndroScience Corporation, H2 2014 42Wounds -
  Pipeline by AnGes MG, Inc., H2 2014 43Wounds -
  Pipeline by APEIRON Biologics AG, H2 2014
  44Wounds - Pipeline by Apricus Biosciences,
  Inc., H2 2014 45

11
List of Figures

• Number of Products under Development for Wounds,
  H2 2014 18Number of Products under Development
  for Wounds - Comparative Analysis, H2 2014
  19Number of Products under Development by
  Companies, H2 2014 20Number of Products under
  Investigation by Universities/Institutes, H2 2014
  26Comparative Analysis by Clinical Stage
  Development, H2 2014 29Comparative Analysis by
  Early Stage Products, H2 2014 30Assessment by
  Monotherapy Products, H2 2014 93Number of
  Products by Top 10 Targets, H2 2014 94Number of
  Products by Stage and Top 10 Targets, H2 2014
  94Number of Products by Top 10 Mechanism of
  Actions, H2 2014 97Number of Products by Stage
  and Top 10 Mechanism of Actions, H2 2014
  97Number of Products by Top 10 Routes of
  Administration, H2 2014 100Number of Products by
  Stage and Top 10 Routes of Administration, H2
  2014 101

12
Related Reports

• Global Neurosurgery Market 2015-2019
• BrainStorm Cell Therapeutics Inc. (BCLI) -
  Financial and Strategic SWOT Analysis Review
• Ampio Pharmaceuticals, Inc. (AMPE) - Financial
  and Strategic SWOT Analysis Review
• MiMedx Group, Inc (MDXG) - Financial and
  Strategic SWOT Analysis Review
• Threshold Pharmaceuticals, Inc. (THLD) -
  Financial and Strategic SWOT Analysis Review

13
Related Reports

• MEI Pharma, Inc. (MEIP) - Financial and Strategic
  SWOT Analysis Review
• Titan Pharmaceuticals, Inc. (TTNP) - Financial
  and Strategic SWOT Analysis Review
• RedHill Biopharma Ltd. (RDHL) - Financial and
  Strategic SWOT Analysis Review
• Pharmaceuticals Healthcare Market Research
  Reports

14

• Wounds - Pipeline Review, H2 2014
• Published Oct 2014 246 Pages
• Wounds - Pipeline Review, H2 2014 report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. 
  Price

Format Price
PDF 2000
Site Licence 4000
Enterprise Wide Licence 6000
15
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news